Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Lung Cancer
Platinum Doublet Chemotherapy plus Pembrolizumab for Patients with SCLC: KEYNOTE-604
Read More
Lung Cancer
Cediranib Combined with Olaparib in Patients with Platinum-Pretreated SCLC
Read More
Lung Cancer
Lurbinectedin for Second-Line Treatment of Patients with Metastatic SCLC
Read More
Lung Cancer
Real-World Data for Nivolumab in Patients with Malignant Mesothelioma
Read More
Lung Cancer
Trastuzumab Deruxtecan in Patients with HER2-Mutated Advanced NSCLC
Read More
Lung Cancer
Pralsetinib and Selpercatinib for NSCLC Patients with RET Gene Fusions
Read More
Lung Cancer
Lorlatinib Improves Outcomes Over Crizotinib in First-Line Setting of ALK-Positive NSCLC
Read More
Lung Cancer
Combination Ramucirumab and Erlotinib for NSCLC with EGFR Exon 19 or Exon 21 Mutations
Read More
Lung Cancer
Capmatinib for Patients with NSCLC with MET Exon 14 Mutation
Read More
Lung Cancer
Anti-TIGIT Antibody Tiragolumab plus Atezolizumab in Patients with PD-L1–Selected NSCLC
Read More
120
121
122
123
124
125
126
Page 123 of 196
Results 1221 - 1230 of 1954
